New achievements in the treatment of chronic obstructive pulmonary disease (results of the UPLIFT study)
- 作者: Ovcharenko SI1, Kapustina VA1, Ovcharenko SI1, Kapustina VA1
-
隶属关系:
- 期: 编号 5 (2009)
- 页面: 33-38
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/276418
- ID: 276418
如何引用文章
全文:
详细
The article discusses the problem of chronic obstructive pulmonary disease (COPD) progression as well as the results of large randomized clinical study UPLIFT studied the long-term effect of tiotropium bromide on pulmonary function in COPD patients. The drug has a high clinical efficacy and safety, reduces mortality from cardiovascular and respiratory complications, and provides sustained improvement of pulmonary function without changing of annual decline rate within 4 years. The tiotropium bromide administration can be recommended as a long-term maintenance therapy in all patients with COPD.
参考
- Хроническая обструктивная болезнь легких. Практическое руководство для врачей. Федеральная программа. 2-е издание, переработанное и дополненное / Под ред. Чучалина А.Г. М., 2004. 64 с.
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2007 (www.goldcopd.com).
- Celli BR, MacNee W, Agustí AG, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
- Casaburi K, Briggs DD, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. A 13-week multicenter trial. Chest 2000;118:1294-302.
- Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
- Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
- Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404.
- O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
- Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127:809-17.
- Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med 2005;143:317-26.
- Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
- Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128:1168-78.
- Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2005;27:547-55.
- Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006;73:420-27.
- Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CarE (SPRUCE) study. Respiratory Research 2007;8:45.
- Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30:472-78.
- Briggs DD, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of Tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005;18:397-404.
- Anzueto A, Tashkin D, Menjoge S, et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005;18:75-81.
- Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004;1:303-12.
- Tashkin DP, Celli B, Senn S, Burkhart D, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
- Wise RA. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Amer J Med 2006:119(10),S4-11.
- Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
- The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-09.
- Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340:1948-53.
- Renkema TEJ, Schouten JP, Koeter GH, et al. Effects of longterm treatment with corticosteroids in COPD. Chest 1996;109:1156-62.
- Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
- Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utilit y Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365:1552-60.
- Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-38.
- Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128(4):2640-46.
- Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008;300(12):1439-50.
- http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2242&mid=1085056570&magid=168&full=1